Immunotherapeutic treatment of superficial bladder tumours using BCG. Preliminary results

Chemotherapy using drugs such as mitomycin C or epirubicin is well known in the treatment of superficial bladder tumours, while use of BCG (Bacillus Calmette-Guérin) in the same pathology is more recent. The first authors to test the BCG were Co? and Feldman, then Zbar fixed the criteria for correct use in the treatment of superficial bladder tumours. First results encouraged the preparation of a drug that could reduce the toxic effects without reducing demonstrated efficacy. Our experience started recently with the introduction onto the market of the Connaught strain, which we prefer to use due to its low toxic effects. We wish to evaluate the tolerability of BCG in a short follow-up period (six months) with cystoscopic controls.